Bloom Energy Corporation [BE] · Equity Underwriting Memo

Bloom Energy Corporation [BE]

Price at publication
$167.03
Enterprise value
$49,192m
TTM revenue
$3,090.8m
EV / Sales
15.9x
Required revenue CAGR
41.3%
Demonstrated CAGR
33.1%
Margin (demonstrated − required)
-8.2pp
Exit multiple
33.2x (GROWTH_MATCHED)
12-month target
$56 - $190 (12-month, band on BE's own multiple range applied to NTM revenue)
12-1 momentum percentile
99.0
Archetype
INFLECTION
Framework
Criteria, 2026-07-29

ANALYSIS, NOT A POSITION. THE Q2 2026 10-Q WAS FILED 2026-07-28, one day after the memo, and it changes two things materially. (1) TTM revenue is $3,090.8m, not the $1,975m the memo used - +56%. (2) THE ORACLE WARRANT IS RESOLVED AND THE EXPECTED CASH NEVER ARRIVES: Oracle completed a CASHLESS exercise on 2026-05-01, five months before the expiry the catalyst calendar was watching, issuing 2,154,231 shares (0.73% dilution) and NO cash - the calendar's $400.0m of expected proceeds do not exist. The unresolved $45.2m warrant gap is explained: a $72.3m net-settlement inducement, net of $17.9m already amortised, against a $251.6m grant-date fair value. $306.5m of contra-revenue remains queued. Quality Criteria FAIL on the gross-margin limb alone (31.5% TTM against the ~50% INFLECTION standard) - a hardware business measured against a software test, reported as FAIL because the input is present and the rule is the rule. Valuation Criteria FAIL: required 41.3% CAGR against 33.1% demonstrated, margin -8.2pp, at a GROWTH_MATCHED 33.2x exit multiple (n=33) implying 107.4 turns of compression from 140.6x. Flip point 44.7x - which independently corroborates the retired instrument's 40.1x break-even. The scandium record is preserved as corrected: scandium appears in one quarter of nine and in ZERO prepared remarks, fifteen months before Hunterbrook, and the sourcing allegation cannot be adjudicated from public filings.

How to read this

This is an analysis, not a position. The memo scores every Criteria and blocks on none of them. Whether an analysis justifies a position is a question about a particular book, and two books answer it differently — so this page carries no Long, Short, Watchlist or Avoid verdict. The previous verdict has been retired.

Every Criteria returns PASS / FAIL / INDETERMINATE, and carries a type. BINDING criteria are admission tests for a long-only absolute-return strategy. MEASURED criteria are always scored and stored, and never block — they inform timing, sizing or a future strategy. A missing input is INDETERMINATE, never FAIL.

Two valuation outputs, over two horizons. The implied-path test (reverse DCF) asks what today's price requires over five years and whether the business has demonstrated it; the 12-month target asks what the name is likely to trade at, on near-term consensus and the name's own multiple history. Neither replaces the other. Sensitivity is run over the exit multiple, never over scenario probabilities.

Momentum is entry timing only. It governs when to enter a position the thesis already justifies, never whether to own one.

Key findings

Sections

Disclosed limitations